Changeflow GovPing Pharma & Drug Safety 5T4 Binding Polypeptides for Cancer Therapy
Routine Notice Added Final

5T4 Binding Polypeptides for Cancer Therapy

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12600794B2 to Abdera Therapeutics for 5T4 binding polypeptides useful for cancer therapy. The 36 claims cover polypeptides conjugated to chelating agents or radionuclide complexes. The patent protects compositions and methods for treating 5T4-expressing cancers.

What changed

USPTO granted patent US12600794B2 to Abdera Therapeutics for compositions comprising 5T4 binding polypeptides useful for cancer therapy. The patent covers 36 claims including unconjugated polypeptides and those conjugated to chelating agents or radionuclide complexes for targeted cancer treatment.

For pharmaceutical and biotech companies developing 5T4-targeting cancer therapeutics, this patent establishes intellectual property protection that may affect freedom-to-operate considerations. Companies pursuing radiopharmaceutical or immunotherapy approaches targeting 5T4 antigens should evaluate potential licensing needs or design-around strategies.

What to do next

  1. Monitor for related patent family filings
  2. Review freedom-to-operate implications for 5T4-targeting therapeutics

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

5T4 binding polypeptides and uses thereof

Grant US12600794B2 Kind: B2 Apr 14, 2026

Assignee

ABDERA THERAPEUTICS INC.

Inventors

Alexander Laurence Mandel, Raja Solomon Viswas, Adam Daniel Judge, Michael J. Abrams, Emma Jane Cummins, Brandon Robert McLeod, Iva Kulic, Douglas Bruce MacKay

Abstract

Described herein are polypeptides that bind to 5T4 useful for cancer therapy. Further disclosed herein are polypeptides that bind to 5T4 that are conjugated to a chelating agent or a radionuclide complex thereof.

CPC Classifications

C07K 16/30 C07K 2317/53 C07K 2317/565 C07K 2317/569 C07K 2317/71 C07K 2317/94 A61K 51/1045 A61K 51/1096 A61K 2121/00 A61K 2123/00 A61P 35/00

Filing Date

2025-07-21

Application No.

19275203

Claims

36

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600794B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Biopharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!